Close Menu

NEW YORK (GenomeWeb) – Illumina said on Monday that it has received regulatory clearance for its MiSeqDx system from the China National Drug Administration, enabling it to sell the system in China for diagnostic testing.

"The clearance of the MiSeqDx in China is a significant milestone for Illumina because it provides more opportunities for NGS," Garret Hampton, executive vice president of clinical genomics at Illumina, said in a statement. "More medical institutions and patients will now have access to the latest NGS technology."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.